Glaukos Co. (NYSE:GKOS) COO Sells $11,587.80 in Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 105 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $110.36, for a total transaction of $11,587.80. Following the completion of the transaction, the chief operating officer now owns 101,845 shares in the company, valued at approximately $11,239,614.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Glaukos Stock Up 0.7 %

GKOS stock opened at $107.64 on Friday. Glaukos Co. has a twelve month low of $54.38 and a twelve month high of $110.73. The company has a quick ratio of 4.68, a current ratio of 5.38 and a debt-to-equity ratio of 0.78. The stock has a market cap of $5.42 billion, a P/E ratio of -37.38 and a beta of 1.08. The business’s 50-day moving average price is $94.66 and its 200-day moving average price is $83.95.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The company had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $79.60 million. During the same period in the previous year, the firm earned ($0.59) earnings per share. The firm’s quarterly revenue was up 15.8% on a year-over-year basis. On average, equities research analysts forecast that Glaukos Co. will post -2.2 EPS for the current year.

Analysts Set New Price Targets

GKOS has been the subject of several analyst reports. Citigroup raised their price target on Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 25th. Truist Financial restated a “buy” rating and set a $125.00 price target (up from $120.00) on shares of Glaukos in a report on Thursday, May 2nd. JPMorgan Chase & Co. raised their price target on Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. Jefferies Financial Group upgraded Glaukos from a “hold” rating to a “buy” rating and raised their price target for the company from $84.00 to $125.00 in a report on Monday. Finally, Wells Fargo & Company raised their price target on Glaukos from $103.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $108.64.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. National Bank of Canada FI purchased a new position in Glaukos in the 4th quarter worth approximately $46,000. GAMMA Investing LLC purchased a new position in Glaukos in the 4th quarter worth approximately $55,000. Quadrant Capital Group LLC lifted its holdings in Glaukos by 54.8% in the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock worth $74,000 after purchasing an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. lifted its holdings in Glaukos by 5,860.0% in the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 1,465 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Glaukos by 17.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock worth $137,000 after purchasing an additional 270 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.